Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 [Yahoo! Finance]
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma